Although with a limited sample number, our results demonstrate that the FJX1-derived peptides are immunogenic and able to induce anti-tumor immune responses in NPC patients against FJX1-expressing tumor cells irrespective of cancer type. The gene discussed is FJX1; the disease is nasopharyngeal carcinoma.